Capmatinib US FDA Label

• Compound: 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
• Description: Capmatinib is a member of the class of imidazotriazines that is imidazo[1,2-b][1,2,4]triazine substituted by 3-fluoro-4-(methylcarbamoyl)phenyl and quinolin-6-ylmethyl groups at positions 2 and 7, respectively. It is a c-Met receptor tyrosine kinase inhibitor used for the treatment of non-small cell lung cancer with MET exon 14 skipping mutation. It has a role as a c-Met tyrosine kinase inhibitor, an antineoplastic agent, a hepatotoxic agent and an apoptosis inducer. It is a member of quinolines, a member of monofluorobenzenes, a member of benzamides, a secondary carboxamide and an imidazotriazine.